Association between iridocyclitis and immune-related disease: A 2-sample Mendelian randomization study.

The genetic basis of iridocyclitis, an inflammatory eye disease, remains poorly understood, particularly in relation to autoimmune diseases. This study aimed to explore the causal associations between 6 immune-related diseases and iridocyclitis using Mendelian randomization (MR). A total of 230 single nucleotide polymorphisms (SNPs) significantly associated with systemic lupus erythematosus, ankylosing spondylitis (AS), rheumatoid arthritis (RA), Graves disease (GD), Crohn disease (CD), and allergic contact dermatitis were identified based on stringent MR assumptions.

Molecular genetics in adult-onset Still's disease: next-generation sequencing in 24 patients and literature review.

Objective: Next-generation sequencing (NGS) panels are increasingly used for the diagnosis of monogenic systemic autoinflammatory diseases (SAIDs). However, their role in patients with adult-onset Still's disease (AOSD) remains unknown. This study aims to assess the usefulness of NGS panels in AOSD patients to improve diagnosis and management of the disease.

Palliative care in advanced systemic rheumatic diseases: an integrated approach.

Despite rapid advances in the field of rheumatology, many patients with rheumatoid arthritis suffer from chronic and debilitating systemic disease, with a high symptom burden and limited life expectancy. In this paper, we demonstrate an approach to managing a patient with rheumatoid arthritis with life-limiting illness for the palliative care physician. In particular, we focus on the systemic nature of rheumatoid arthritis and nuances around medication management towards the end of life.

High throughput multiplex immunoassays stratify patients according to symptom burden across the anti-Ro positive systemic autoimmune rheumatic disease spectrum.

Anti-Ro/SS-A antibodies are prevalent across systemic autoimmune rheumatic diseases (SARDs) and may signify a distinctive phenotype. This study aimed to identify protein biomarkers associated with symptom burden and health-related quality of life (HR-QoL), and use protein-based stratification to identify clinically meaningful clusters and inflammatory pathways implicated. Anti-Ro positive SARD patients were enrolled in a 6-month pilot study.

Evaluation of uric acid levels and other biochemical parameters among Gout patients with Ketogenic diet in Erbil province.

Gout is a systemic disorder that occurs due to an accumulation of uric acid crystals in the tissues. The association between the Ketogenic diet and uric acid concentration has been poorly established. This study aims to evaluate and assess the association of Serum uric acid and other variables with ketogenic diet among Gout patients in comparison with Healthy control subjects.

Sjögren's Disease and Gastroesophageal Reflux Disease: What Is Their Evidence-Based Link?

Sjögren's disease (SjD), or primary Sjögren's syndrome (pSS), is a heterogeneous chronic autoimmune disorder with multiple clinical manifestations that can develop into non-Hodgkin's lymphoma in mucosa-associated lymphoid tissue. SjD is one of the autoimmune diseases with the maximum delayed diagnosis due to its insidious onset, heterogeneous clinical features and varied course. It is increasingly recognized that extraglandular manifestations represent a clinical challenge for patients with SjD.

The Challenges of Local Intra-Articular Therapy.

Fibroblast-like synoviocytes (FLSs) are among the main disease-driving players in most cases of monoarthritis (MonoA), oligoarthritis, and polyarthritis. In this review, we look at the characteristics and therapeutic challenges at the onset of arthritis and during follow-up management. In some cases, these forms of arthritis develop into autoimmune polyarthritis, such as rheumatoid arthritis (RA), whereas local eradication of the RA synovium could still be combined with systemic treatment using immunosuppressive agents.

Targeted Therapy of Antibody-Induced Autoimmune Arthritis Using Peptide-Guided Nanoparticles.

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints and it affects over 18 million people worldwide. Despite the availability of a variety of potent drugs for RA, over 30-40 percent of patients fail to achieve adequate remission, and many patients suffer from systemic adverse effects. Thus, there is an urgent need for a joint-targeted drug delivery system.

Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia.

Background: Mycophenolate mofetil is used for the prevention of solid organ transplant rejection and for other indications, such as systemic lupus erythematosus (SLE).

Objective: To determine the prescription patterns of mycophenolate mofetil in a group of Colombian patients.

Methods: This was a cross-sectional study of patients receiving mycophenolate mofetil between 2021 and 2022.

[Between the normal and the pathological: The concept of pre-disease applied to systemic autoimmune rheumatic diseases].

The incidence of systemic autoimmune diseases is constantly rising. They are chronic diseases requiring prolonged treatment, with considerable psychosocial impact. While attention to the promising results obtained with CAR-T cells in refractory patients is justified, it seems important not to overlook the opportunities for prevention based on the identification of a pre-disease state.

Serum IL-40 increases in patients with rheumatoid arthritis and correlates with some clinical characteristics and comorbidities.

The role of Interleukin-40 (IL-40) in rheumatoid arthritis (RA) is not well understood, and this study was designed to explore serum IL-40 levels in RA patients to assess its potential as a disease biomarker. In this research, serum IL-40 levels were determined using enzyme-linked immunosorbent assay in 116 patients with RA, 40 with osteoarthritis (OA), 29 with systemic lupus erythematosus (SLE), and 66 healthy controls (HCs). Paired serum samples were collected from 86 of the 116 patients treated during follow-up visits at week 12.

siRNA-based nanotherapeutic approaches for targeted delivery in rheumatoid arthritis.

Rheumatoid arthritis (RA), characterized as a systemic autoimmune ailment, predominantly results in substantial joint and tissue damage, affecting millions of individuals globally. Modern treatment modalities are being explored as the traditional RA therapy with non-specific immunosuppressive drugs showcased potential side effects and variable responses. Research potential with small interfering RNA (siRNA) depicted potential in the treatment of RA.